Colleen Silk/LinkedIn
Nov 4, 2025, 08:22
Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”Rare diseases remind us that science must never overlook the few.
Hemophilia B with inhibitors affects only a small number of people, yet its impact is profound.
We are proud to have been recognized as a finalist for the 2025 Prix Galien US Award for Best Orphan/Rare Disease Product.
Novo Nordisk believes that every person—no matter how rare their condition—deserves the best that science can offer.
We’re proud of this recognition and grateful to the Prix Galien Foundation for honoring innovation that makes a real difference.”
More winner stories featured in Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM